It can be surprising to learn that lung cancer can develop in people who have never smoked. In fact, up to 20% of lung ...

Biodesix (NASDAQ:BDSX) outlined its current commercial focus, growth priorities, and financial milestones during a ...

The biopsy came back positive. It’s lung cancer.” Countless people in our community hear these words no one ever expects.

Study to evaluate clinical performance of CyPath® Lung for the early detection of lung cancer in high-risk patientsMurtha Cancer Center Research Program at Uniformed Services University of the Health ...

Biodesix (NASDAQ:BDSX) is focused on developing diagnostic tests intended to improve patient outcomes by answering specific ...

As a nonsmoker lung cancer hasn't been a concern of mine, but I recently heard it can affect people who have never smoked. If someone is concerned about lung cancer, what symptoms should they watch ...

Imagine you go to the healthcare provider because you have a bad cough, or maybe you fell and hurt your ribs.

Affinity Technologies (NASDAQ:BIAF) announced on March 10, 2026, the launch of a large longitudinal clinical study involving 2,000 patients to evaluate the performance of its CyPath® Lung technology ...

Many eligible patients miss lung cancer screening due to low awareness and systemic barriers, putting underserved groups at higher risk for late-stage disease. She also explained the differences in ...

Three medical societies claim recent studies have overestimated the potential harms from lung cancer screening and may be ...

Detailed price information for Bioaffinity Technologies Inc (BIAF-Q) from The Globe and Mail including charting and trades.

LCS commercial launch is ongoing in U.S. following FDA 510(k) clearance CE-marking regulatory process is on-going with a ...